{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:34:17Z","timestamp":1722641657525},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11899-019-00555-3","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T09:07:27Z","timestamp":1576746447000},"page":"477-479","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?"],"prefix":"10.1007","volume":"14","author":[{"given":"Robert Peter","family":"Gale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"\u2022 Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137 Normal survival of Swedes with CML.","journal-title":"J Clin Oncol"},{"key":"555_CR2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"555_CR3","doi-asserted-by":"crossref","unstructured":"\u2022 Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlman R, Jiang Q, et al. Do persons with chronic myeloid leukaemia really have normal survival? Leukemia. 2019. Decreased survival of US persons with CML.","DOI":"10.1038\/s41375-019-0699-y"},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"\u2022 Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multi-centre, non-randomized trial. Lancet Oncol. 2018;19:747\u201357 Large trial of therapy-free remission.","journal-title":"Lancet Oncol"},{"key":"555_CR6","unstructured":"Saglio G, Gale RP. Prospects for achieving therapy-free remission in chronic myeloid leukaemia. Br J Haematol In press."},{"key":"555_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447\u201359.","journal-title":"Lancet"},{"key":"555_CR8","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"24","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210\/abl gene of the Philadelphia chromosome. Science. 1990;24:824\u201330.","journal-title":"Science"},{"key":"555_CR10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"555_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"The Cancer Genome Atlas Research Network","year":"2012","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519\u201325.","journal-title":"Nature"},{"issue":"4","key":"555_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Adam Abeshouse","year":"2015","unstructured":"The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. doi https:\/\/doi.org\/10.1016\/j.Cell.2015.10.025.","journal-title":"Cell"},{"key":"555_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"issue":"Suppl 1","key":"555_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/10428199309047878","volume":"11","author":"H Preisler","year":"1993","unstructured":"Preisler H, Raza A. An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system. Leuk Lymphoma. 1993;11(Suppl 1):145\u201350.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"555_CR15","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","volume":"104","author":"Georgios Nteliopoulos","year":"2019","unstructured":"Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydio R, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2018.200220.","journal-title":"Haematologica"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"\u2022 Branford S, Kim DDH, Apperley JF, Edie CA, Mustjoki S, Ong ST. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33:1835\u201350 A review of the impact of mutations other than BCRABL1 on prognosis of persons with CML.","journal-title":"Leukemia"},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"\u2022 Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49 The impact of BCRABL1 detection on therapy outcomes.","journal-title":"Mol Cancer"},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Simoneti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543\u201356.","journal-title":"Leukemia"},{"key":"555_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53\u201361. https:\/\/doi.org\/10.1182\/blood-2015-08-604520.","journal-title":"Blood"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/leu.2017.181","volume":"31","author":"R Bejar","year":"2017","unstructured":"Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia. 2017;31:1869\u201371.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00555-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:38:30Z","timestamp":1608251910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00555-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00555-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}